Bothpatientshavechronicconditionsandthushavetotaketheirmedicationregularly.docx

       Both patients have chronic conditions and thus have to take their medication regularly. This may lead to a reduced level of compliance, especially for the first patient who has a muted-drug therapy for her different condition. The patient should be advised to comply with their medications by showcasing the importance of the medicines and the effects of irrational use. The patients should also be advised to report on sides effects (Talebreza et al., 2020).

The medications should be reviewed contextually as per each patient presentation. The first patient has the desire to conceive (Antimisiaris & Cutler, 2017). The steps taken would be to review the medications to identify any side effects that could inhibit conception or lead to the teratogenic impacts or other adverse effects during pregnancy. Possible drug interactions that could impact fertilization or fetus development should also be considered (Antimisiaris & Cutler, 2017). The patient should also be advised how her current condition, such as hypertension, could negatively influence her pregnancy and possible precautions (Talebreza et al., 2020). The second patient with Benign Prostatic hyperplasia should be reviewed to determine the possible side effects of the medication offered (Haas et al., 2018). Presentation with lower urinary tract infection symptoms should also be investigated since it points to urine retention and potentially reduced effectiveness of terazosin.

 

                                                                                             References

Antimisiaris, D., & Cutler, T. (2017). Managing polypharmacy in the 15-minute office visit. Primary Care: Clinics in Office Practice44(3), 413-428.

Haas, D. M., Marsh, D. J., Dang, D. T., Parker, C. B., Wing, D. A., Simhan, H. N., ... & Reddy, U. M. (2018). Prescription and other medication use in pregnancy. Obstetrics and gynecology131(5), 789.

Talebreza, S., & McPherson, M. L. (2020). Recognizing and managing polypharmacy in advanced illness. The Medical clinics of North America104(3), 405-413.